Sonoma Pharmaceuticals, Inc.
SNOA
$2.97
$0.051.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.75M | 3.56M | 3.58M | 3.39M | 3.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.75M | 3.56M | 3.58M | 3.39M | 3.44M |
| Cost of Revenue | 2.23M | 2.29M | 2.22M | 2.09M | 2.35M |
| Gross Profit | 1.53M | 1.27M | 1.36M | 1.31M | 1.09M |
| SG&A Expenses | 1.77M | 1.87M | 1.71M | 2.01M | 2.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.41M | 4.60M | 4.43M | 4.56M | 4.85M |
| Operating Income | -656.00K | -1.03M | -850.00K | -1.17M | -1.41M |
| Income Before Tax | -528.00K | -919.00K | -463.00K | -997.00K | -1.36M |
| Income Tax Expenses | 248.00K | 9.00K | 147.00K | 146.00K | -292.00K |
| Earnings from Continuing Operations | -776.00K | -928.00K | -610.00K | -1.14M | -1.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -776.00K | -928.00K | -610.00K | -1.14M | -1.07M |
| EBIT | -656.00K | -1.03M | -850.00K | -1.17M | -1.41M |
| EBITDA | -625.00K | -998.00K | -815.00K | -1.13M | -1.37M |
| EPS Basic | -0.48 | -0.63 | -0.59 | -1.34 | -1.39 |
| Normalized Basic EPS | -0.20 | -0.39 | -0.28 | -0.73 | -1.11 |
| EPS Diluted | -0.48 | -0.63 | -0.59 | -1.34 | -1.39 |
| Normalized Diluted EPS | -0.20 | -0.39 | -0.28 | -0.73 | -1.11 |
| Average Basic Shares Outstanding | 1.61M | 1.46M | 1.03M | 851.50K | 767.00K |
| Average Diluted Shares Outstanding | 1.61M | 1.46M | 1.03M | 851.50K | 767.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |